Delivery Order SPE2DB22D1017-SPE2DB25FG6GL

Award Date 7/1/25
Potential Completion Date 7/2/25
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, to support federal healthcare programs. The contract has a ceiling value of $2,678.62 and a period of performance through January 7, 2025. The contract is a firm-fixed-price delivery order, with no set-aside...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $2,419.87 and a period of performance through October 28, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $43,433.74 and a performance period through May 2, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $71,009.21 and an ultimate completion date of February 10, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has a ceiling value of $1,117.80 and a performance period extending through May 8, 2025. It is a firm fixed-price contract, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,160.96, is for the delivery of RESTASIS 0.05% eye emulsion, with a completion date of February 15, 2023. The contract is a firm fixed-price, delivery order type, and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $49,706.46 and a period of performance through May 22, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $4,748.43 and a period of performance ending on September 4, 2024. It is a firm-fixed-price contract. This delivery order is issued under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,789.55 contract is for the supply of RESTASIS 0.05% eye emulsion. It is a firm-fixed price contract with a completion date of September 20, 2023. The contract is not designated under any set-aside program. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $1,891.07 and an ultimate completion date of September 20, 2024. This is a firm fixed-price contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal contracts and Indefinite Delivery Contracts (IDCs) by various defense and civilian...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FG6GL
    Delivery Order

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $2,214.15 and a completion date of July 2, 2025. The contract is a firm fixed-price arrangement, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a significant vendor for the DLA, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.

Generated 9/30/25, 9:47 AM